Appeal 2007-2532
Application 10/608,791
38. Jackson argues that Krieger does not mention transitions between
detectable memory states arising from changes in chemical bonds, and that
changes in resistivity do not imply changes in chemical bonds or organic-
polymer doping. (Br. at 12–13.)
39. Moreover, according to Jackson, Krieger does not mention or suggest
that the state change is reversible. (Br. at 13.)
40. Jackson argues that claims 2–32 all depend ultimately from claim 1,
and that the rejection must fail for them as well. (Br. at 13.)
41. Jackson argues that "specific rejections of many of the dependent
claims are completely unsupported by the cited references." (Br. at 13.)
42. Jackson, however, argues only the rejection of claim 4 specifically.
43. According to Jackson, "[n]either Figure 5 of Krieger nor any text
referencing Figure 5 in Krieger teach[es], disclose[s], mention[s], or
suggest[s] a memory cell in which organic-polymer dopants are active in one
memory state and inactive in another memory state." (Br. at 13.)
C. Discussion
Bristol-Myers Squibb Co. v. Ben Venue Labs., Inc., 246 F.3d 1368,
1374, 58 USPQ2d 1508, 1512 (Fed. Cir. 2001) ("A claim is anticipated if
each and every limitation is found either expressly or inherently in a single
prior art reference." (Citation omitted.)) During prosecution, “the PTO
applies to the verbiage of the claims the broadest reasonable meaning of the
words in their ordinary usage as they would be understood by one of
ordinary skill in the art, taking into account whatever enlightenment by way
of definitions or otherwise that may be afforded by the written description
contained in the applicant’s specification.” In re Morris, 127 F.3d 1048,
11
Page: Previous 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 Next
Last modified: September 9, 2013